We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
+ 34-608-087-655
nsaglio@yahoo.co.uk
Title Image

Blog

Home  /  FDA   /  FDA authorized Vela Diagnostics’ Sentosa SQ HIV Genotyping Assay

FDA authorized Vela Diagnostics’ Sentosa SQ HIV Genotyping Assay

The Food and Drug Administration has given the go-ahead to what it calls the first next-generation sequencing test for detecting mutations that enable the most common strain of HIV to become immune to drugs.

The FDA said that it had authorized marketing of Singapore-based Vela Diagnostics’ Sentosa SQ HIV Genotyping Assay, describing it as the first HIV drug-resistance assay to use NGS technology. The U.S. approval is not the first for the assay – the company announced that Thailand’s drug regulatory agency approved it in August. Regulators in Singapore and Australia approved it in 2017.

Read More